Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Amortization of Deferred Charges (2021 - 2023)

GeneDx Holdings has reported Amortization of Deferred Charges over the past 3 years, most recently at $130000.0 for Q3 2023.

  • Quarterly results put Amortization of Deferred Charges at $130000.0 for Q3 2023, changed 0.0% from a year ago — trailing twelve months through Sep 2023 was $518000.0 (up 14.35% YoY), and the annual figure for FY2022 was $518000.0, up 684.85%.
  • Amortization of Deferred Charges for Q3 2023 was $130000.0 at GeneDx Holdings, up from $129000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for WGSWW hit a ceiling of $131000.0 in Q4 2022 and a floor of $66000.0 in Q4 2021.
  • Median Amortization of Deferred Charges over the past 3 years was $129000.0 (2022), compared with a mean of $121375.0.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 98.48% in 2022 and later changed 0.0% in 2023.
  • GeneDx Holdings' Amortization of Deferred Charges stood at $66000.0 in 2021, then soared by 98.48% to $131000.0 in 2022, then decreased by 0.76% to $130000.0 in 2023.
  • The last three reported values for Amortization of Deferred Charges were $130000.0 (Q3 2023), $129000.0 (Q2 2023), and $128000.0 (Q1 2023) per Business Quant data.